Hypoxic Ischemic Encephalopathy

Normal BrainNormal Brain
HIE + HypothermiaHIE + Hypothermia
HIE + RLS-0071HIE + RLS-0071
Hypoxia + Ligation Hypoxia +
Hypoxia + Ligation + Hypothermia Hypoxia +
Ligation +
Hypoxia + Ligation + RLS-0071 Hypoxia +
Ligation +

Our Goals:

  • We aim to significantly increase the survival rate of babies born with birth asphyxia world-wide
  • We aim to enhance the neurocognitive outcomes of HIE survivors
  • We aim to make RLS-0071 available to professionals and families around the world

ReAlta is currently enrolling the STAR Phase 2 trial for RLS-0071 in newborns with HIE in neonatal intensive care units across the U.S.  More information about the STAR trial is available on clinicaltrials.gov (NCT05778188) https://clinicaltrials.gov/study/NCT05778188

ReAlta Has Strong Support From Key HIE Patient Advocacy Groups

ReAlta has partnered with Hope for HIE, a leading organization providing resources for awareness, education, advocacy, and support surrounding neonatal and pediatric HIE. Serving a worldwide community, the organization provides a comprehensive support network for families, collaborates with research and medical professionals, and leads advocacy initiatives to reduce incidence and increase quality of life for those affected by HIE. Hope for HIE is a 501(c)3 non-profit. For more information, please visit www.hopeforhie.org.

Hypoxic Ischemic Encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.

Learn More
Acute Exacerbations of COPD

Acute Exacerbations of COPD (AE COPD) affect individuals suffering from COPD, leading to worsening lung function and hospitalization. This inflammatory disease is primarily driven by neutrophils recruited into the lungs.

Learn More
Graft-versus-Host Disease

Graft-versus-Host Disease (GvHD) is a common disease following bone marrow transplantation where the transplanted white blood cells begin to attack the host body including skin, liver and intestines.

Learn More
Platelet Refractoriness

Platelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.

Learn More